Defining Minimal Genomics Content for All Tumor Types | GenomeWeb
March 03, 2016
Sponsored by
Agilent Technologies

Defining Minimal Genomics Content for All Tumor Types


Assistant Professor in the Division of Cancer Biology in the Department of Radiation Oncology at Emory University. 

This webinar discusses the use of a hybrid capture-based FFPE DNA sequencing methodology with the potential for advancing precision oncology studies. 

The goal of precision oncology is to identify and target molecular events that give rise to tumor growth and progression. Although the overall success of this approach for all tumor types is debated, it is clear that in some instances this approach has yielded dramatic results. The mutation spectrum of cancers encompasses driver missense and indel mutations, copy number abnormalities and coding fusions, many of which are still routinely analyzed with independent molecular pathology and cytogenetic assays. Moving forward, it is clear that if we are to improve the outcomes of the majority of patients with recalcitrant tumors, we need to update the histological diagnostic standards to incorporate molecular markers to propose more rational approaches to combined therapies. 

This webinar focuses on the use of a hybrid capture-based FFPE DNA sequencing methodology to move toward this goal. Research into the technical feasibility, cost-effectiveness, and bioinformatics analysis workflows are described. 

Sponsored by

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.

Sponsored by

This webinar will discuss how next-generation sequencing and digital PCR can be used in a complementary manner for liquid biopsies in order to improve patient care.

Sponsored by
Personal Genome Diagnostics

This webinar will discuss genomic methods to elucidate the molecular mechanisms underlying acquired resistance to immuno-oncology (IO) therapies.


This webinar describes the optimization and validation of two commercially available next-generation sequencing assays that may be used to guide personalized cancer treatment.